US government reportedly investigating allegations that CVS refilled prescriptions, submitted Medicare insurance claims without patients' approval

Cindy Allen

Cindy Allen

Oct 18, 2012 – Thomson Reuters

LONDON , October 18, 2012 () – The U.S. government is investigating allegations that CVS Caremark Corp refilled prescriptions and submitted insurance claims to Medicare without getting approval from patients, the Los Angeles Times reported.

The newspaper, quoting an official with knowledge of the matter, said an investigation had been launched by the Inspector General for the U.S. Department of Health and Human Services, which is in charge of looking into potential Medicare fraud. http://link.reuters.com/wyp33t

Officials at the agency and CVS Caremark, the second-biggest U.S. drug store chain, could not be reached for comment outside regular U.S. business hours.

Medicare is the U.S. health program for the elderly and disabled.

CVS Caremark agreed to pay $5 million in January to settle charges of inaccurate pricing of some drugs for the elderly and the disabled, ending a wide-ranging, multi-year probe into its business practices.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Share:

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025 795

+1 (310) 558 0008
+1 (310) 558 0080 (FAX)

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.